A Phase III Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer. Verified January 2012 by Eisai Inc.
EISAI Protocol (PDF)
A multicentre randomised trial of high versus low dose radioiodine, with or without rhTSH, for remnant ablation following surgery for thyroid cancer. Chief Investigator: Dr Ujjal Mallick and Dr Clive Harmer
HiLo Summary (PDF)